This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Morphic Holding Management

Management criteria checks 3/4

Morphic Holding's CEO is Praveen Tipirneni, appointed in Jul 2015, has a tenure of 9.08 years. total yearly compensation is $8.91M, comprised of 6.9% salary and 93.1% bonuses, including company stock and options. directly owns 1.31% of the company’s shares, worth €34.05M. The average tenure of the management team and the board of directors is 3.3 years and 7.2 years respectively.

Key information

Praveen Tipirneni

Chief executive officer

US$8.9m

Total compensation

CEO salary percentage	6.9%
CEO tenure	9.1yrs
CEO ownership	1.3%
Management average tenure	3.3yrs
Board average tenure	7.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Praveen Tipirneni's remuneration changed compared to Morphic Holding's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-US$180m
Mar 31 2024	n/a	n/a	-US$161m
Dec 31 2023	US$9m	US$614k	-US$152m
Sep 30 2023	n/a	n/a	-US$136m
Jun 30 2023	n/a	n/a	-US$130m
Mar 31 2023	n/a	n/a	-US$64m
Dec 31 2022	US$11m	US$602k	-US$59m
Sep 30 2022	n/a	n/a	-US$56m
Jun 30 2022	n/a	n/a	-US$51m
Mar 31 2022	n/a	n/a	-US$106m
Dec 31 2021	US$5m	US$579k	-US$96m
Sep 30 2021	n/a	n/a	-US$92m
Jun 30 2021	n/a	n/a	-US$61m
Mar 31 2021	n/a	n/a	-US$50m
Dec 31 2020	US$4m	US$559k	-US$45m
Sep 30 2020	n/a	n/a	-US$47m
Jun 30 2020	n/a	n/a	-US$61m
Mar 31 2020	n/a	n/a	-US$55m
Dec 31 2019	US$788k	US$498k	-US$43m
Sep 30 2019	n/a	n/a	-US$29m
Jun 30 2019	n/a	n/a	-US$27m
Mar 31 2019	n/a	n/a	-US$24m
Dec 31 2018	US$2m	US$402k	-US$24m

Compensation vs Market: Praveen's total compensation ($USD8.91M) is above average for companies of similar size in the German market ($USD2.46M).

Compensation vs Earnings: Praveen's compensation has been consistent with company performance over the past year.

CEO

Praveen Tipirneni (56 yo)

9.1yrs

Tenure

US$8,907,684

Compensation

Dr. Praveen P. Tipirneni, M.D., M.B.A., has been Independent Director at Tectonic Therapeutic, Inc. He serves as an Independent Director at Panacea Acquisition Corp. II since April 6, 2021. He serves as Ch...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Praveen Tipirneni	CEO, MD & Director	9.1yrs	US$8.91m	1.31% $ 34.1m
Bruce Rogers	President	2.3yrs	US$4.88m	0.30% $ 7.8m
Timothy Springer	Founder	10yrs	US$539.99k	15.2% $ 395.7m
Marc Schegerin	CFO & COO	4.3yrs	US$4.65m	0.075% $ 2.0m
Robert Farrell	Senior VP of Finance & Chief Accounting Officer	4.6yrs	US$4.03m	0.023% $ 610.8k
Blaise Lippa	Chief Scientific Officer	2.3yrs	no data	no data
William DeVaul	General Counsel & Secretary	5.5yrs	US$2.24m	0.039% $ 1.0m
Aaron Pelta	Senior Vice President of Business & Corporate Development	2.3yrs	no data	no data
Joanne Gibbons	Senior Vice President of Regulatory Affairs	2.3yrs	no data	no data
Simon Cooper	Chief Medical Officer	less than a year	no data	no data

3.3yrs

Average Tenure

55yo

Average Age

Experienced Management: 31Y's management team is considered experienced (3.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Praveen Tipirneni	CEO, MD & Director	9.1yrs	US$8.91m	1.31% $ 34.1m
Timothy Springer	Founder	9.2yrs	US$539.99k	15.2% $ 395.7m
Norbert Bischofberger	Independent Director	5.2yrs	US$545.74k	0% $ 0
Joseph Slattery	Independent Director	5.3yrs	US$560.74k	0.018% $ 469.9k
Martin Edwards	Independent Director	3.7yrs	US$547.49k	0.0047% $ 123.1k
Gustav Christensen	Independent Chairman	8.6yrs	US$586.49k	0.20% $ 5.2m
Amir Nashat	Independent Director	7.2yrs	US$544.99k	0.00029% $ 7.6k
Scott L. Friedman	Member of Scientific Advisory Board	no data	no data	no data
Ulrich von Andrian-Werburg	Member of Scientific Advisory Board	no data	no data	no data
Shelia Violette	Member of Scientific Advisory Board	no data	no data	no data
Albert Robichaud	Member of Scientific Advisory Board	no data	no data	no data
Yury Popov	Member of Scientific Advisory Board	no data	no data	no data

7.2yrs

Average Tenure

63yo

Average Age

Experienced Board: 31Y's board of directors are considered experienced (7.2 years average tenure).

This company listing is no longer active

Morphic Holding Management

Management criteria checks 3/4

Key information

Recent management updates

Morphic Holding, Inc., Annual General Meeting, Jun 04, 2024

Morphic Therapeutic Appoints Simon Cooper as Chief Medical Officer

Insufficient new directors

Morphic Holding, Inc. Announces Chief Executive Officer Changes

Morphic Holdings Inc. Announces Chief Executive Officer, Praveen Tipirneni Suffered an Emergent Medical Event and Taking Medical Leave of Absence

Morphic Therapeutic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs

Recent updates

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others.

New major risk - Share price stability

Eli Lilly and Company (NYSE:LLY) entered into an agreement and plan of merger to acquire Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others for $3.2 billion.

Morphic Holding, Inc., Annual General Meeting, Jun 04, 2024

Morphic Therapeutic Appoints Simon Cooper as Chief Medical Officer

Full year 2023 earnings released: US$3.59 loss per share (vs US$1.55 loss in FY 2022)

Insufficient new directors

Morphic Holding, Inc. Announces Chief Executive Officer Changes

Third quarter 2023 earnings released: US$0.73 loss per share (vs US$0.78 loss in 3Q 2022)

Morphic Holdings Inc. Announces Chief Executive Officer, Praveen Tipirneni Suffered an Emergent Medical Event and Taking Medical Leave of Absence

Second quarter 2023 earnings released: US$0.92 loss per share (vs US$0.70 profit in 2Q 2022)

First quarter 2023 earnings released: US$0.90 loss per share (vs US$0.85 loss in 1Q 2022)

Full year 2022 earnings released: US$1.55 loss per share (vs US$2.67 loss in FY 2021)

Morphic Holding, Inc. announced that it expects to receive $29.999954 million in funding

Morphic Therapeutic AnnouncesInitiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis

Third quarter 2022 earnings released: US$0.78 loss per share (vs US$0.69 loss in 3Q 2021)

Morphic Therapeutic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022

Morphic Therapeutic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022

Second quarter 2022 earnings released: EPS: US$0.70 (vs US$0.77 loss in 2Q 2021)

Morphic Therapeutic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs

Morphic Holding, Inc. Announces Management Appointments

First quarter 2022 earnings released: US$0.85 loss per share (vs US$0.64 loss in 1Q 2021)

Morphic Holding, Inc., Annual General Meeting, Jun 08, 2022

Morphic Therapeutic Announces Management Appointments

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Morphic Holding, Inc. Announces Retirement of Dr. Nilesh Kumar from the Board and Resign as Member of the Board and the Audit and Nominating and Governance Committees

Third quarter 2021 earnings released: US$0.69 loss per share (vs US$0.17 profit in 3Q 2020)

Founder recently bought €3.6m worth of stock

Second quarter 2021 earnings released: US$0.77 loss per share (vs US$0.52 loss in 2Q 2020)

Morphic Holding, Inc.(NasdaqGM:MORF) dropped from Russell 3000E Index

Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 At ECCO'21 Virtual Congress

Founder recently bought €8.7m worth of stock

Independent Director has left the company

First quarter 2021 earnings released: US$0.64 loss per share (vs US$0.56 loss in 1Q 2020)

Morphic Announces Clinical Results Update

Independent Director recently bought €59k worth of stock

Full year 2020 earnings released: US$1.47 loss per share (vs US$2.69 loss in FY 2019)

Revenue misses expectations

Morphic Holding, Inc. Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057

New 90-day high: €68.50

New 90-day high: €28.20

Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin Program

New 90-day high: €27.20

Morphic Holding, Inc. Appoints Martin Edwards to Serve on the Board as A Class II Director

New 90-day high: €25.60

Third quarter 2020 earnings released: EPS US$0.17

Revenue beats expectations

Morphic Announces Presentation of New Data Supporting Development of MORF-057 at UEG Week Virtual 2020

Morphic Therapeutic Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of MORF-057

Morphic Holding, Inc.(NasdaqGM:MORF) dropped from Russell 3000 Value Index

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age